Q-omics provides the consensus-scored GPN1 profile across patient tissues and cancer cell-line models. GPN1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GPN1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, GPN1 RNA expression shows 19,145 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, HNSC, and ACC as cancer lineages where GPN1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GPN1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GPN1 survival associations across molecular data types. GPN1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GPN1 RNA expression–survival associations across cancer types. High GPN1 expression shows unfavorable associations in MESO, LIHC, ACC, CESC, LGG and KICH. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GPN1 RNA expression.
This table summarizes GPN1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GPN1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GPN1 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, COAD, LIHC and LUAD. The HNSC box plot shows higher GPN1 RNA expression in tumor versus normal tissue (log2 FC = +0.982, t-test p < 0.001).
This table shows molecular features associated with GPN1 in patient tissues and cancer cell lines. In patient samples, GPN1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, GPN1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
